SIRT2 and osteoporosis: Notably, treatment with AGK2 or LRG1-sEVs conferred a therapeutic benefit in osteoporosis, including in animal models and human primary cell cultures, corroborating targeting hepatocyte SIRT2 or sEV-LRG1 as a promising therapeutic modality in primary osteoporosis.